

Soraya Puglisi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3776248/publications.pdf>

Version: 2024-02-01

62
papers

800
citations

471509

17
h-index

580821

25
g-index

66
all docs

66
docs citations

66
times ranked

773
citing authors

#	ARTICLE	IF	CITATIONS
1	Adrenal Incidentalomas are Tied to Increased Risk of Diabetes: Findings from a Prospective Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e973-e981.	3.6	69
2	Age-dependent and sex-dependent disparity in mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: an international, retrospective, cohort study. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 499-508.	11.4	55
3	New perspectives for mitotane treatment of adrenocortical carcinoma. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2020, 34, 101415.	4.7	49
4	Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence. <i>European Journal of Endocrinology</i> , 2019, 180, 387-396.	3.7	38
5	Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System. <i>Frontiers in Endocrinology</i> , 2021, 12, 738848.	3.5	36
6	Acromegaly Is More Severe in Patients With <i>AHR</i> or <i>AIP</i> Gene Variants Living in Highly Polluted Areas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 1872-1879.	3.6	34
7	Decision-making for adrenocortical carcinoma: surgical, systemic, and endocrine management options. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 1125-1133.	2.4	34
8	Mitotane Concentrations Influence the Risk of Recurrence in Adrenocortical Carcinoma Patients on Adjuvant Treatment. <i>Journal of Clinical Medicine</i> , 2019, 8, 1850.	2.4	31
9	Analysis of GPR101 and AIP genes mutations in acromegaly: a multicentric study. <i>Endocrine</i> , 2016, 54, 762-767.	2.3	30
10	Adrenocortical Carcinoma with Hypercortisolism. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 395-407.	3.2	29
11	Mitotane Concentrations Influence Outcome in Patients with Advanced Adrenocortical Carcinoma. <i>Cancers</i> , 2020, 12, 740.	3.7	28
12	Effects of mitotane on the hypothalamic-pituitary-adrenal axis in patients with adrenocortical carcinoma. <i>European Journal of Endocrinology</i> , 2017, 177, 361-367.	3.7	25
13	Unwanted Hormonal and Metabolic Effects of Postoperative Adjuvant Mitotane Treatment for Adrenocortical Cancer. <i>Cancers</i> , 2020, 12, 2615.	3.7	24
14	Increased frequency of the rs2066853 variant of aryl hydrocarbon receptor gene in patients with acromegaly. <i>Clinical Endocrinology</i> , 2014, 81, 249-253.	2.4	21
15	Hypertension and Acromegaly. <i>Endocrinology and Metabolism Clinics of North America</i> , 2019, 48, 779-793.	3.2	20
16	Levoketoconazole improves clinical signs and symptoms and patient-reported outcomes in patients with Cushing's syndrome. <i>Pituitary</i> , 2021, 24, 104-115.	2.9	20
17	Thyroid and colorectal cancer screening in acromegaly patients: should it be different from that in the general population?. <i>European Journal of Endocrinology</i> , 2020, 183, D1-D13.	3.7	19
18	How to improve effectiveness of pegvisomant treatment in acromegalic patients. <i>Journal of Endocrinological Investigation</i> , 2018, 41, 575-581.	3.3	18

#	ARTICLE	IF	CITATIONS
19	Pathophysiology of light phenotype SARS-CoV-2 interstitial pneumonia: from histopathological features to clinical presentations. <i>Pulmonology</i> , 2022, 28, 333-344.	2.1	17
20	Cardiovascular events in acromegaly: distinct role of Agatston and Framingham score in the 5-year prediction. <i>Endocrine</i> , 2014, 47, 206-12.	2.3	16
21	GSTP1 gene methylation and AHR rs2066853 variant predict resistance to first generation somatostatin analogs in patients with acromegaly. <i>Journal of Endocrinological Investigation</i> , 2019, 42, 825-831.	3.3	16
22	Recovery of Adrenal Insufficiency Is Frequent After Adjuvant Mitotane Therapy in Patients with Adrenocortical Carcinoma. <i>Cancers</i> , 2020, 12, 639.	3.7	16
23	Results of the ADIUVO Study, the First Randomized Trial on Adjuvant Mitotane in Adrenocortical Carcinoma Patients. <i>Journal of the Endocrine Society</i> , 2021, 5, A166-A167.	0.2	16
24	What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question. <i>Journal of Personalized Medicine</i> , 2021, 11, 269.	2.5	14
25	Analysis of BCL1, N363S and ER22/23EK Polymorphisms of the Glucocorticoid Receptor Gene in Adrenal Incidentalomas. <i>PLoS ONE</i> , 2016, 11, e0162437.	2.5	13
26	Preoperative treatment with metyrapone in patients with Cushing's syndrome due to adrenal adenoma: a pilot prospective study. <i>Endocrine Connections</i> , 2018, 7, 1227-1235.	1.9	13
27	Molecular Mechanisms of Mitotane Action in Adrenocortical Cancer Based on In Vitro Studies. <i>Cancers</i> , 2021, 13, 5255.	3.7	13
28	Oligometastatic adrenocortical carcinoma: the role of image-guided thermal ablation. <i>European Radiology</i> , 2020, 30, 6958-6964.	4.5	10
29	Autonomous hypercortisolism: definition and clinical implications. <i>Minerva Endocrinologica</i> , 2018, 44, 33-42.	1.8	9
30	Prolonged Adrenal Insufficiency After the Discontinuation of Mitotane Therapy. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2020, 20, 485-487.	1.2	7
31	Glucocorticoid Receptor Antagonism Upregulates Somatostatin Receptor Subtype 2 Expression in ACTH-Producing Neuroendocrine Tumors: New Insight Based on the Selective Glucocorticoid Receptor Modulator Relacorilant. <i>Frontiers in Endocrinology</i> , 2021, 12, 793262.	3.5	7
32	Sex Differences on Mitotane Concentration and Treatment Outcome in Patients with Adrenocortical Carcinoma. <i>Life</i> , 2021, 11, 266.	2.4	6
33	Is Follow-up of Adrenal Incidentalomas Always Mandatory?. <i>Endocrinology and Metabolism</i> , 2020, 35, 26.	3.0	6
34	Limited Role of Hair Cortisol and Cortisone Measurement for Detecting Cortisol Autonomy in Patients With Adrenal Incidentalomas. <i>Frontiers in Endocrinology</i> , 2022, 13, 833514.	3.5	6
35	First randomized trial on adjuvant mitotane in adrenocortical carcinoma patients: The Adjuvo study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 1-1.	1.6	6
36	Long-term cardiometabolic outcome in patients with pituitary adenoma diagnosed in childhood and adolescence. <i>Pituitary</i> , 2021, 24, 483-491.	2.9	5

#	ARTICLE	IF	CITATIONS
37	A Multicenter Epidemiological Study on Second Malignancy in Non-Syndromic Pheochromocytoma/Paraganglioma Patients in Italy. <i>Cancers</i> , 2021, 13, 5831.	3.7	5
38	Determination of salivary cortisol to assess time-related changes of the adrenal response to stress in critically ill patients. <i>European Journal of Internal Medicine</i> , 2019, 68, 66-70.	2.2	3
39	Cardiometabolic Risk in Acromegaly: A Review With a Focus on Pasireotide. <i>Frontiers in Endocrinology</i> , 2020, 11, 28.	3.5	3
40	What factors have impact on glucocorticoid replacement in adrenal insufficiency: a real-life study. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 865-872.	3.3	3
41	First report on persistent remission of acromegaly after withdrawal of long-term pegvisomant monotherapy. <i>Growth Hormone and IGF Research</i> , 2019, 45, 17-19.	1.1	2
42	Involvement of 27-Hydroxycholesterol in Mitotane Action on Adrenocortical Carcinoma. <i>Cells</i> , 2020, 9, 885.	4.1	2
43	Multiple rebound-associated vertebral fractures after denosumab discontinuation: is prompt antiresorptive therapy always recommended, even when the risk of fracture seems low? A case report. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2021, 21, .	1.2	2
44	Mitotane: new facts for an old drug. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2019, 8, 145-151.	1.4	1
45	May an adrenal incidentaloma change its nature?. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 1301-1307.	3.3	1
46	Results of the ADIUVO trial, the first randomized study on post-operative adjuvant mitotane in patients with adrenocortical carcinoma. <i>Endocrine Abstracts</i> , 0, , .	0.0	1
47	Preoperative treatment with metyrapone in patient with Cushing's syndrome due to adrenal adenoma: a pilot prospective study. <i>Endocrine Abstracts</i> , 0, , .	0.0	1
48	Adrenal Incidentalomas. , 2018, , 303-307.		0
49	Adrenocortical Carcinoma: Diagnosis and Therapy. , 2019, , 308-316.		0
50	The management of post-operative recurrences in patients with adrenocortical carcinoma (ACC): The experience of San Luigi Hospital. <i>Endocrine Abstracts</i> , 0, , .	0.0	0
51	Incidental detection of adrenal hyperplasia and mortality in patients with suspected SARS-CoV-2 Infection. <i>Endocrine Abstracts</i> , 0, , .	0.0	0
52	Adrenal Hyperplasia as Possible Predictor of Mortality in Patients Admitted for Suspected SARS-Cov-2 Infection: A Prospective Study. <i>Journal of the Endocrine Society</i> , 2021, 5, A76-A76.	0.2	0
53	Adrenocortical Cancer. , 2021, , 319-326.		0
54	Effects of cyberknife radiotherapy treatment of pituitary adenomas. <i>Endocrine Abstracts</i> , 0, , .	0.0	0

#	ARTICLE	IF	CITATIONS
55	Assessment of the hypothalamic pituitary adrenal axis in patients receiving adjuvant mitotane treatment after radical resection of adrenocortical carcinoma. Endocrine Abstracts, 0, , .	0.0	0
56	Resistance to somatostatin analogues is associated with GSTP1 gene methylation and AHR rs2066853 variant in acromegaly patients. Endocrine Abstracts, 0, , .	0.0	0
57	Outcome of adjuvant mitotane therapy in patients with adrenocortical carcinoma: the experience of San Luigi Gonzaga Hospital. Endocrine Abstracts, 0, , .	0.0	0
58	SAT-365 Prevalence and Clinical Features of Adrenal Incidentalomas: A Prospective Study in an Unselected Population. Journal of the Endocrine Society, 2019, 3, .	0.2	0
59	Management of adjuvant mitotane therapy for adrenocortical carcinoma: a survey in Italy. Endocrine Abstracts, 0, , .	0.0	0
60	How do sex and BMI affect glucocorticoid treatment in adrenal insufficiency?. Endocrine Abstracts, 0, , .	0.0	0
61	Management of mitotane for advanced adrenocortical carcinoma: a survey in Italy. Endocrine Abstracts, 0, , .	0.0	0
62	Effects of different therapeutic approaches on cardiovascular risk in patients with acromegaly: Results of a multicentric study. Endocrine Abstracts, 0, , .	0.0	0